A novel pathogenic variant in the MARVELD2 gene causes autosomal recessive non-syndromic hearing loss in an Iranian family by Taghipour-Sheshdeha, Afsaneh et al.
Contents lists available at ScienceDirect
Genomics
journal homepage: www.elsevier.com/locate/ygeno
A novel pathogenic variant in the MARVELD2 gene causes autosomal
recessive non-syndromic hearing loss in an Iranian family
Afsaneh Taghipour-Sheshdeha,1, Fatemeh Nemati-Zargarana,1, Narges Zarepoura,
Parisa Tahmasebib, Nader Sakic, Mohammad Amin Tabatabaiefard,e, Javad Mohammadi-Aslf,⁎⁎,
Morteza Hashemzadeh-Chaleshtoria,⁎
a Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
bDepartment of Biology, Faculty of Sciences, Ilam University, Ilam, Iran
cHearing Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
d Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
e Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan,
Iran
fDepartment of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
A R T I C L E I N F O
Keywords:
ARNSHL
NGS
Genetic linkage analysis
DFNB loci
A B S T R A C T
Background and aims: Hearing loss (HL) is the most common sensorineural disorder and one of the most common
human defects. HL can be classiﬁed according to main criteria, including: the site (conductive, sensorineural and
mixed), onset (pre-lingual and post-lingual), accompanying signs and symptoms (syndromic and non-syn-
dromic), severity (mild, moderate, severe and profound) and mode of inheritance (Autosomal recessive, auto-
somal dominant, X-linked and mitochondrial). Autosomal recessive non-syndromic HL (ARNSHL) forms con-
stitute a major share of the HL cases. In the present study, next-generation sequencing (NGS) was applied to
investigate the underlying etiology of HL in a multiplex ARNSHL family from Khuzestan province, southwest
Iran.
Methods: In this descriptive study, 20 multiplex ARNSHL families from Khuzestan province, southwest of Iran
were recruited. After DNA extraction, genetic linkage analysis (GLA) was applied to screen for a panel of more
prevalent loci. One family, which was not linked to these loci, was subjected to Otogenetics deafness Next
Generation Sequencing (NGS) panel.
Results: NGS results showed a novel deletion-insertion variant (c.1555delinsAA) in the MARVELD2 gene. The
variant which is a frameshift in the seventh exon of the MARVELD2 gene fulﬁlls the criteria of being categorized
as pathogenic according to the American College of Medical Genetics and Genomics (ACMG) guideline.
Conclusion: NGS is very promising to identify the molecular etiology of highly heterogeneous diseases such as
HL. MARVELD2 might be important in the etiology of HL in this region of Iran.
1. Introduction
Hearing loss (HL) is one of the most common congenital impair-
ments, occurring in approximately 1–2 in 1000 newborns worldwide
[1,2]. Half of the cases of this highly heterogeneous disease are at-
tributed to genetic causes. Diﬀerent criteria are routinely used for
classiﬁcation of HL. Genetic HL is divided into syndromic and non-
syndromic forms considering other accompanying signs and symptoms
[3]. Based on the site of the defect, HL is categorized as conductive,
sensorineural and mixed. According to the time of onset, it is either pre-
lingual or post-lingual. In terms of severity, HL is classiﬁed as mild,
moderate, severe and profound. Finally, HL can have diﬀerent modes of
inheritance, including autosomal recessive, autosomal dominant, X-
linked or mitochondrial [4,5].
HL is a main health problem in developing countries. Obviously,
early onset HL prevents proper speech acquisition and negatively af-
fects the quality of life and the socioeconomic position of the child [4]
while early diagnosis can easily result in speech development and
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prevents further problems [6]. Non-syndromic forms (NSHL) constitute
over 70% of HL cases and pattern of inheritance of nearly 80% of NSHL
is autosomal recessive (ARNSHL) [7,8]. Previous studies have estab-
lished involvement of about %1 of human genes in hearing develop-
ment, defects in which cause HL. So far, 88 out of 148 known loci for
NSHL are known to contribute to ARNSHL forms, which are usually
more severe than other forms. To date, 64 genes have been identiﬁed to
contribute to ARNSHL and 30 genes to autosomal dominant NSHL [9].
NSHL loci are numbered according to the order of discovery and clas-
siﬁed bad on pattern of inheritance. DFNB and DFNA represent Loci
with recessive and dominant inheritance, respectively. Likewise, loci
with X-linked inheritance are shown as DFNX [10]. Although there are
numerous genes contributing to HL, a few constitute a signiﬁcant por-
tion of the etiology [11]. Mutations in the GJB2 gene are the main cause
of ARNSHL all over the world, and, on average, cause about 18.5% of
HL etiology in the Iranian population [12–14]. These ﬁndings empha-
size the various mutational loads in NSHL genes in diﬀerent popula-
tions. Genetic linkage analysis (GLA) has been used to detect the genetic
cause of HL in diﬀerent populations uncovering a considerable number
of recessive HL genes for decades [15]. However, the approach has
largely been superseded by the novel Next generation sequencing (NGS)
technologies which oﬀer a breakthrough in molecular research, facil-
itating more rapid diagnosis of diﬀerent genetic diseases [16]. Although
exome sequencing covers thousands annotated exons, the sequence
coverage of regions of interest may be decreased in targeted regions. In
comparison, targeted enrichment sequencing covers the target regions
more eﬃciently and could reduce the analysis duration and cost
[17–19]. NGS platforms have made their way into clinical laboratories,
especially in diagnostic testing for hereditary disorders like HL [20,21].
NGS methods produce huge amount of data which need to be ﬁltered
and correctly classiﬁed. There are appropriate guidelines for NGS data
interpretation [22,23].
The Iranian population with over 80 million people, and with many
ethnic groups and high frequency of consanguineous marriages oﬀers a
valuable genetic resource to study ARNSHL [14]. Some of NSHL genes
were initially discovered in the Iranian population through genetic
linkage analysis (GLA) or have revealed many novel mutations [24–27].
MARVELD2 (DBNB49) contributes to ARNSHL. MARVELD2 encodes
a membrane protein named tricellulin, a member of the tight junction-
associated Marvel protein family which is found at the tight junctions
between epithelial cells. Thus far, 6 mutations have been reported for
MARVELD2 gene to cause ARNSHL in diﬀerent studies. Mutations in
MARVELD2 were the cause of HL in diﬀerent studies from Pakistan, Iran
and Central European Roma [28–31].
The present study is part of a larger study, which aimed to complete
the genetic map of HL in Iran by investigating the pedigrees of families
with hearing impaired members in each province. The result of this
study would have implications in improved genetic counseling and
prevention of HL using pre-implantation genetic diagnosis (PGD). In
this study, 20 GJB2 negative multiplex families from Khuzestan pro-
vince, southwest Iran, were subjected to GLA to screen for more pre-
valent DFNB loci. A family (Named Ahv-12, Ahv stands for Ahvaz the
birthplace of this family) with high Slink value not linked to the studied
loci was subjected to NGS in order to clarify the etiology of HL and a
novel pathogenic variant was found in MARVELD2 gene (DFNB49).
2. Materials and methods
2.1. Family ascertainment and clinical diagnosis
Twenty consanguineous multiplex families (190 individuals) with at
least 3 hearing impaired individuals in each family were recruited in
this study. Families were from Khuzestan province with a high rate of
consanguinity among the people. These families were selected from a
collection of 50 families with hearing impaired individuals who had
been visited by a specialist and the type of HL was conﬁrmed as
ARNSHL and had been subjected to Sanger sequencing for GJB2 and to
GLA for a panel of 11 common loci and were not linked to any of them.
Aﬀected members showed bilateral sensorineural moderate-to-pro-
found HL. Pure tone audiometry and otoscopy were performed for all
Fig. 1. Ahv-12 family SLINK value. The power to detect linkage depends on a variety of factors, such as the structure of the pedigree, the number of aﬀected
individuals and the informativeness of the markers. This image is the output of FastSlink v2.51 (easyLINKAGE program package). The maximum Slink value for Ahv-
12 family is 2.8.
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the individuals by standard procedures. Simulation of linkage (SLINK)
value was calculated for each pedigree as previously mentioned (Fig. 1
shows Ahv-12 family SLINK) [11]. Peripheral blood samples (5 ml) of
all the 190 individuals were collected in EDTA-containing CBC tubes.
A written informed consent was ﬁlled out by all participants. The
project was approved by the Review Boards of three diﬀerent uni-
versities (Ahvaz Jundishapur University of Medical sciences,
Shahrekord University of Medical Sciences and Isfahan University of
Medical Sciences).
2.2. DNA extraction
DNA was extracted from 0.5 ml of blood sample for each individual
by a standard phenol-chloroform procedure [32]. DNA purity and
concentration was determined using a Nanodrop 2000 spectro-
photometer (Nonodrop 2000 Thermo Scientiﬁc, USA) and its quality
was checked on 1% agarose gel.
2.3. Genotyping STR markers and linkage analysis
In the previous study DNA sequencing of the coding region of GJB2
was performed in one aﬀected member of each family, using Sanger
sequencing [11] and a panel of 11 loci was checked including: DFNB3,
DFNB4, DFNB7/11, DFNB8/10, DFNB9, DFNB21, DFNB59, DFNB63,
DFNB24, DFNB39, DFNB53.
In this study, we further examined the families using a panel of 4
other DFNB loci, including: DFNB35, DFNB42, DFNB48 and DFNB98
before performing NGS. Linkage analysis was performed using at least
two informative Short Tandem Repeat (STR) markers located at or
tightly linked to each locus. Each speciﬁc STR marker can have variable
number of repeats among indviduals. NCBI MapViewer was used to
choose the best STR markers. Primer sequences were obtained from the
Probe database. Primer sequences are shown in Table 1. Touchdown
PCR was performed in a thermal cycler machine (ASTEC PC-818, Fu-
kuka, Japan) to amplify STR markers. For all the subjects, PCR products
were genotyped via polyacrylamide gel electrophoresis. Diﬀerent STRs
had diﬀerent sizes, heterozygosity and patterns but we used 10%
polyacrylamide (19:1) to detect STR bands. As some STRs were unin-
formative in some of families we had to test more STRs to ﬁnd at least 2
informative markers for each locus among families to conﬁrm or reject
linkage (Fig. 2). Haplotyping and logarithm of the odds (LOD) score
calculations were done either to conﬁrm or reject linkage.
Two-point and multi-point parametric LOD scores under a recessive
model were, respectively, calculated by Superlink version 1.6 and
Simwalk version 2.91(assuming a risk allele frequency of 0.001 and
complete penetrance) (easyLINKAGE program package) [33,34]. Sim-
walk and Haplopainter software version 029.5 were used to reconstruct
and visualize haplotypes, respectively [35].
2.4. NGS, data analysis and in silico prediction
NGS was performed using the Otogenetics Deafness Gene Panel
(Otogenetics, USA), which uses custom oligonucleotide-based target
capture of the coding regions of the 129 genes followed by Illumina
HiSeq 2000 sequencing with> 100 fold coverage at every target base
pair [36]. In summary, genomic DNA was fragmented to 200–300 base
pairs, Illumina library was made and DNA fragments were captured
using a customized array designed to target all exons, splicing sites and
ﬂanking intronic sequences of 129 deafness genes. The paired-end reads
of 2×100 base pairs were then sequenced.
The released raw data were converted to the FASTQ ﬁle.
Bioinformatics analysis included using BWA for read mapping to the
reference genome (hg19, NCBI Build 38), Picard for removal of dupli-
cate reads and GATK for variant calling. Variants were annotated with
the Annovar software.
Homozygous missense, start codon change, splice site, nonsense,
stop loss and indel variants with MAF < 1%, were ﬁltered in dbSNP
version 137, 1000 genomes database, NHLBI GO exome sequencing
project (ESP) and exome aggregation consortium (ExAC). Several
computational prediction tools were used to evaluate the pathogenic
eﬀect of the variants. We also used several online software tools in-
cluding: FATHMM, PANTHER, SIFT, PROVEAN, MutationAssessor, I-
Mutant2.0, PHD-SNP, PolyPhen-2 and Mutation taster for the in-
vestigation of the missense variant (Table 2). Next, the variants were
investigated in the Human Gene Mutation Database (HGMD) and the
literature to seek the novelty of the variant or its association with HL.
2.5. Sanger sequencing and NGS data validation
Only 3 out of all reported variants showed homozygote pattern, of
which one was not found in the above-mentioned databases. Candidate
variants were validated by Sanger sequencing in the proband, his par-
ents and his aﬀected uncle and aunt. The SeqMan software version 5.00
© (DNASTAR, Madison, WI, USA) was used to analyze the sequencing
results. The American College of Medical Genetics and Genomics
(ACMG) guidelines were used to interpret variants and classify them
[23].
2.6. Co-segregation analysis
The following primers were designed to amplify the last exon of
MARVELD2 gene F: 5'-GCTGTAGAGACTTTTGCTATG-3′ R: 5′- CCTTG
TACATCCCAATTC -3′. Co-segregation analysis was done for Ahv-12
family using Sanger sequencing. In addition, the variant in the
MARVELD2 gene was checked in a cohort of 50 healthy ethnically-
matched controls using Sanger sequencing.
3. Results
3.1. Clinical evaluation and Slink result
The type of HL was detected as ARNSHL and its phenotype was
bilateral moderate-to-profound HL. Pedigree of Ahv-12 family is shown
in Fig. 3. The audiogram of the proband (Ahv-12) is shown in Fig. 4.
3.2. Linkage analysis
A panel of 4 loci was screened in this study. Polyacrylamide gel
genotyping was done for all families and no linkage was found for the
interested loci.
3.3. NGS data analysis
Out of all the variants found in this study, one met the criteria for
further analyses. Table 3 summarizes the most probable candidates
with in silico prediction.
A deletion of nucleotide c.1555G, replaced by nucleotides AA,
changing ..AGAATGATCCTA.. to ..AGAATAAATCCTA..
(NM_001038603.2:c.1555delinsAA). It causes frameshift
(NP_001033692.2: p.Asp519Lysfs*12) in the seventh exon of the
MARVELD2 gene. It creates alternation of 11 amino acids downstream
of the insertion and leads to an early stop codon resulting in a truncated
protein with 529 residues (versus 558 residues in the intact protein).
This practically means the complete change of the last exon and dele-
tion of about 30% of the occludin-ELL domain, which is essential for the
protein interactions and tight junction function. This deletion-insertion
mutation was assessed as being deleterious by mutation taster as well as
several other prediction tools.
The variant was found to be co-segregating with the disease in the
family: heterozygous in parents but homozygous in the three patients.
The electropherogram of the last exon of MARVELD2 gene is shown in
Fig. 5.
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Table 1
4 DFNB loci information. Details of screening markers are shown.
Locus (gene) MARKER Forward and Reverse Primer sequences PCR product range
DFNB98
)TSPEAR)
D21S1261 F:GCAGCAGCACATCAACATTC
R:GAAGAGATGTTGAACTTCACTG
194–204
D21S171 F: GATCAAGTTAAGAGGAGGCT
R: GTGGGCTGCTGCTATCTTTG
200–204
D21S1890 F:TGACCACAGATTTCCCAATC
R:AAAAACACTCTGAACGATTAAGG
143–173
D21S1260 F: TCCAAGGGGTTCATCC
R: CCCAAGGCACTGTTCC
200–214
D21S1446 F:ATGTACGATACGTAATACTTGACAA
R: GTCCCAAAGGACCTGCTC
209–223
D21S1912 F: GAGCCCACCCTGGTAAC
R: CCCTCATACAGATTTAAAACACAC
173–205
DFNB48 (CIB2) D15S1027 F: CTGAAAACCAGCCCACTC
R: GAGTCCCTGGAGAGCCC
196–210
D15S984 F: GAGGCTCCGAGGGCAG
R: GCAGACACGCTCGCAT
200–210
D15S1001 F: TGGGCCTTGTGATTTTAG
R: CATCTGTGTGTCTGTGACTG
259–270
D15S114 F:AGAATGAGCAGCACTGTTTG
R:TTGTCACTGCTTTTCTCTGC
177–191
D15S973 F:ATCCACCTGACTCAAGGA
R:TTCTCCATCAGTAAATTGCG
250–265
D15S991 F: AGCTTGGTGACTCTATCAGGGTG
R: AACTGGCTGGTCTCTATTATCTGCG
198–220
D15S1023 F: GGTATTGTTTTGGACCACATCTTAG
R: GGGAGGCTGAGACAGTTTC
272–293
DFNB35
(ESRRB)
D14S53 F:CTTTCCCCAGTGAAGTTGC
R:ACACTGCACTCCTACTCTG
135–155
D14S61 F: CCTGCTAAAAGTCAAGTGGG
R: AATGGCGTATCAGAGAGGAA
197–227
D14S1036 F:AAGCCCCTTTGTGACTGAC
R:GCCCATGTGATATTTGGTG
203–217
D14S279 F: GTGACCTCAGCATGTATTACTC
R: CAGGTATTCCCAATATGCAGC
196–212
D14S270 F:CCACTAATGATAACATTGTCGC
R: AGAGGCAGGTGAATGACT
214–224
D14S983 F: TGGACTGGTTAGCCTCAGTG
R: GCATCAACTGGCTTCCAATC
222–270
DFNB42 (ILDR1) D3S3720 F: CAAGCAATCCTCCAGCCTC
R: GCTGTATCTGAATCTAAAGCCT
216–236
D3S3576 F: GATCTAGTTGGCAAGGCG
R: TTGGACTCGAGCAATCC
202–214
D3S3674 F: GCCTTGGAAAACCTTGAA
R: TTGCCTGCAACAATGATTAC
181–205
D3S3709 F:TGCATGTGCGTGTATATTTG
R:ACAGTTGTGAGACACCACCTATT
145–183
D3S3552 F:GCCACTCCCAAATGTCTG
R:GACTGGAACTTGATTGCC
161–177
D3S1278 F: GGACACATGCTCCTGGAA
R: TGCACTAVAGGGCAGTTG
203–231
D3S3645 F: GCAGTGCTGAAAGATGGC
R: ACCTGGACTTGGGATGG
164–212
Fig. 2. Allele segregation in Ahv-12 family on 10% polyacrylamide (19:1) gel. No linkage was found. Key: M (Mother), F (Father), P (Patient with HL) and N
(Normal). D15S1027 (DFNB48 (CIB2 gene)) genotyping (A). F, M, N1, N2 and P2 are heterozygous while P1 is homozygous (A). D21S1446 (DFNB98) TSPEAR gene))
genotyping (B). F, M, P1 and N2 are heterozygous; while P2 and N1 are homozygous (B). P2 and N1 have the same pattern and the other patient shows hetero-
zygosity. Patterns of allele segregation rejected linkage.
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4. Discussion
>148 loci are known to cause hearing loss (HL) among which, 88
loci are attributed to ARNSHL [37]. DFNB1 (GJB2) is the most common
known locus involved in HL worldwide, accounting for about 50% of
ARNSHL cases in Western countries [11,38]. Even though mutations of
GJB2 are the most common cause of ARNSHL in Iran, they constitute
about 18.5% of HL cases which highlights the role of other genes in Iran
[12,13].
In this study, a consanguineous multiplex ARNSHL family negative
for a panel of loci (investigated by GLA to ﬁnd the cause of ARNSHL)
was selected for further study using NGS by the Otogenetic HL gene
panel and a novel deletion-insertion variant in the last exon of
MARVELD2 gene was found in this family.
The human MARVELD2 gene (the DFNB49 locus) is located on the
chromosome 5q13.2 (Chromosome 5: 68,710,939–68,740,157) and
encodes the MARVELD2/tricellulin protein [39]. The gene contains 7
exons and has 2 validated transcript variants [40,41]. MARVELD2, a
transmembrane protein is composed of 558 amino acids and is mainly
concentrated in tricellular tight junctions in the epithelial cells, in-
cluding hair cells, cochlear supporting cells and marginal cells of stria
vascularis [31,39]. Tight junction proteins (TJPs) have a deﬁnite role in
regulating ionic and other molecular traﬃc. The inner ear epithelium is
the main site for several tight junction proteins [42]. The MARVELD2
protein loss of function especially Occludin-ELL domain has been re-
ported to be responsible for HL in several Pakistani families [30,31] and
one Iranian family [28]. The locus DFNB49 was initially mapped to the
long arm of chromosome 5 by Ramezan et al. who reported 2 Pakistani
families linked to this region [40,43]. Riazuddin et al. identiﬁed the
MARVELD2 gene in this locus to cause HL in Pakistani families [31].
Riazuddin reported 4 diﬀerent mutations in this gene in Pakistani
families. IVS3-1G > A which resulted in the deletion of the ﬁrst 17
nucleotides of exon 4 caused HL in a Pakistani family. Another reported
variant was IVS4+ 2delTGAG that resulted in a premature stop codon
found in 2 Pakistani HL families. IVS4+2 T > C was the cause of HL
in 4 families resulting in premature termination of mRNA translation.
c.1498C > T, a nonsense mutation in exon 5, caused HL in one
Pakistani family [31]. Chishti et al. found 2 Pakistani families linked to
DFNB49. Two diﬀerent mutations were the causes of HL in these fa-
milies. One was IVS4+2 T > C which had been previously reported
by Riazuddin et al. [31] but the other, IVS4+ 1G > A, was a new
mutation generating a truncated protein [44]. A single-base pair dele-
tion (c.1543delA) in exon 6 of the MARVELD2 gene which produces a
premature stop codon (p.Lys517ArgfsX16) was reported as the cause of
ARNSHL in an Iranian family by Babanejad et al. [28]. To date, 6 dif-
ferent pathogenic variants of the human MARVELD2 gene have been
identiﬁed in families with moderate-to-profound HL [28,30,31,44]
(Table 5 and Fig. 6). Variants in the majority of TJPs have been asso-
ciated with HL [30,39]. Riazuddin et al. accentuated the important role
of occluding domian in the proper function of the tricellulin protein,
and conﬁrmed that the defect in this domain is associated with
ARNSHL. Although it was conﬁrmed that mutations inMARVELD2 gene
cause HL in humans and mice according to the study accomplished by
Riazuddin, Tric−/− mice were generated by Kamitani et al. that suf-
fered from an early-onset progressive HL associated with the destruc-
tion of cochlear hair cells probably owing to the disturbance in the
epithelial barrier function in the organ of Corti. As the only pathological
phenotype in their study was HL and loss of hair cells in Tric−/−mice,
thus, contribution of tricellulin to the tight junctions especially in the
organ of Corti was concluded [45].
Table 2-
The list of databases and prediction tools used in this study.
Tools/Databases Electronic Address
1 SIFT http://sift.jcvi.org
2 FATHMM http://fathmm.biocompute.org.uk
3 PANTHER http://www.pantherdb.org/tools/csnpScoreForm.
jsp
4 MutationAssessor http://mutationassessor.org/r3
7 PolyPhen-2 http://genetics.bwh.harvard.edu/pph2
8 PROVEAN http://provean.jcvi.org/index.php
9 Mutation taster http://www.mutationtaster.org
10 I-mutant http://folding.biofold.org/i-mutant/i-mutant2.0.
html
11 String http://string-db.org
12 Extasy http://extasy.esat.kuleuven.be
13 Swiss-model https://swissmodel.expasy.org/interactive
14 1000 Genomes Project http://www.1000genomes.org/
15 DbSNP http://www.ncbi.nlm.nih.gov/SNP/
16 InterPro https://www.ebi.ac.uk/interpro/
17 Oligoanalyzer https://eu.idtdna.com/calc/analyzer
18 MFEprimer-2.0 http://biocompute.bmi.ac.cn/CZlab/MFEprimer-2.
0/
19 NCBIprimer blast http://www.ncbi.nlm.nih.gov/tools/primer-blast/
Fig. 3. The pedigree of Ahv-12 pedigree showing consanguinity among the nuclear families. Co-segregation of the novel deletion-insertion variant (c.1555delinsAA)
with ARNSHL is shown in the pedigree. Individual #22 is the proband. Hearing impaired Individuals are shown with Filled symbols. (+) shows the new variant and
(−) shows the wild-type allele.
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In the present study, a novel deletion-insertion mutation
(c.1555delinsAA) in MARVELD2 was found to be the cause of HL in
Ahv-12 family. The deletion-insertion variant was suggested to be de-
leterious by mutation prediction tools such as Mutation Taster. Even
though this variant was not a missense mutation, we used diﬀerent in
silico prediction tools to determine the impact of one single amino acid
alternation on the MARVELD2 protein functions and structure
(Table 4). Surprisingly, it was reported as deleterious.
Fig. 4. Ahv-12 proband's audiogram conﬁrming moderate-to-profound sensorineural defect in both ears. In air conduction testing, the symbol O stands for the right
ear and the symbol X represents the left ear. A > symbol is used for the left ear and a < symbol is used for the right ear in bone-conduction vibration. The frequency
and the loudness/intensity of sound are measured by Hertz (Hz) and decibels (db HL), respectively. The area above the symbols represents the sounds that the
proband cannot hear and the area under the symbols indicates all of the sounds that the proband can hear.
Table 3
Bioinformatics analyses of the potential candidate variants found in this study.
WHRN MYO15A OTOF LHFPL5
Zygosity Homozygote Homozygote Heterozygote Heterozygote
Variant type Missense Missense Missense Missense
Variant P562A A595T R773C H15Y
1000 Genome Population Allele Frequency 0.07 0.49 0.01 0
Sift Tolerated/1 Damaging/0.05 Damaging/0.02 Damaging/0.04
Polyphen Possibly damaging/0.532 Possibly damaging/0.68 Possibly damaging/0.99 Possibly damaging/0.98
Provean Neutral/−2.18 Neutral/−0.68 Deleterious/−4 Deleterious/−3.15
Mutation assessor Medium/2.36 Low/1.44 Medium/2.29 Medium/2.48
Panther Probably benign Probably benign Probably damaging Probably damaging
Fathmm Tolerated/3.71 Damaging/−2.47 Tolerated/−1.47 Tolerated/−1.14
I-mutant Decrease stability Decrease stability Decrease stability Decrease stability
Fig. 5. Electropherogram of the last exon of the MARVELD2 gene. Number 1, 2, 3 and 4 are the electropherogram of the patient, control individual and patient's
father and mother, respectively. Heterozygosity of the deletion-insertion variant (c.1555delinsAA) in parents (heterozygote carrier), homozygous in the proband and
homozygous wild-type alleles in a control individual are shown. Arrows show the position of deleted and inserted nucleotides.
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As the variant was in the last exon of the gene, the conservation of
the exon as well as whole Occludin-ELL domain was checked more
closely. The last exon of MARVELD2 gene is highly conserved among
species (Table 6) and has a key role in interaction between MARVELD2
and TJP1 (ZO-1) protein and also for the adequate function of tricel-
lular tight junctions [46]. Defect in MARVELD2 and TJPs lead to
moderate-to-profound forms of ARNSHL [45]. The C-terminal sequence
of tricellulin and occludin which consists of 130 aa is completely con-
served and contains a domain necessary for its interaction with ZO-1 a
TJ plaque protein (Fig. 7) [47]. Even the last 35 amino acids of the
MARVELD2 protein are reported as highly conserved by Interpro and
Pfam [48]. Full-length tricellulin is necessary for proper tightness of
TJPs of Corti. Truncated proteins are unable to associate with ZO-1, ZO-
2 and ZO-3 [31,47]. The MARVELD2 protein interacts with TJP1 via the
occludin domain, as described before. Length reduction of TRIC pro-
tein, which was the result of this frameshift variant, deteriorates the
eﬀective association between tricellulin and other TJPs.
The alteration we have found in this study is located in the cytosolic
domain of the protein, which is highly vital for protein interactions and
based on the previous ﬁndings we expect it to cause HL. The variant
(p.Lys517ArgfsX16), reported by Babanejad et al., resulted in a pre-
mature stop codon [28], is close to this novel variant and both have
similar eﬀect on shortening the occludin domain.
The ACMG guidelines were used for variant interpretation [23] The
deletion-insertion variant is a null allele leading to a truncated protein
(PVS1), the variant was seen in all aﬀected family members and was not
detected in the controls (PS4), the variant is co-segregating with the
disease in all aﬀected family members (PP1) and bioinformatics ana-
lyses support a deleterious eﬀect on MARVELD2 protein (PP3). It is
located in a validated domain (PM1), this variant reduces the length of
Fig. 6. Sites of known variants of the MARVELD2 gene. The deletion-insertion variant c.1555delinsAA (p.Asp519Lysfs*12) which is located in exon 7, and 6
previously known variants are shown. Exons 5, 6 and 7 make the occludin domain.
Table 4
The impact of c.1555delinsAA, only assessed for D519K substitution, on the
MARVELD2 protein predicted by in silico tools.
PANTHER SIFT POLYPHEN PROVEAN MUTATION
TASTER
Possibly
damaging
Damaging/
0.006
Probably
Damaging/1
Deleterious/
−5.43
Disease
causing
Table 5
The known mutations of the MARVELD2 gene.
Variant Type Study
IVS3-1G > A Cryptic splice-acceptor site within
exon 4 of TRIC
Riazuddin et al.
(2006)
IVS4+ 2 T > C Exon4 skipping
c.1498C > T
(p.R500X)
Transition in exon 5
IVS4_2delTGAG Premature stop codon
IVS4+1G > A Splice site mutation Chishti et al. (2007)
p.Lys517Argfs*16 Frameshift Babanejad et al.
(2012)
p.Asp519Lysfs*12 Frameshift Current study
Table 6
Occludin-ELL domain alignment among diﬀerent species shows conservation of the last exon of the MARVELD2 gene.
Species match Gene Change 
point
(residue)
Alignment
Human ENSG000001
52939
519 IHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRI
QEYDKVMNWDVQGYS*
Mutated Partly 
conserved 
ENSG000001
52939
519 IH EEFKKKKNKSYISGKKRTL*
P.troglody
tes
all 
conserved
ENSPTRG000
00016951
520 IHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRI
QEYDKVMNWDVQGYS
M.mulatta all 
conserved
ENSMMUG0
0000009158
518 IHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRI
QEYDKVMNWDVQGYS
F.catus all 
conserved
ENSFCAG0
0000002488
318 IHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRI
QEYDKVMNWNVQGYS
M.muscul
us
Partly 
conserved
ENSMUSG0
0000021636
516 IHEEFKKKKNDPSFLEKKERCDYLKNKLSHIKQRI
QEYDKVMNWDTQGY
T.rubripes Partly 
conserved
ENSTRUG0
0000018563
520 IHEEFKKKKNDPTFLEKKERCEYLKSKLSHIKQKI
QEYDKVMEWN-DGY
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the protein (PM4) and was not reported by dbSNP database and 1000
genome project (PM2) [23]. Thus, the variant is categorized as being
pathogenic.
Mašindová et al. studied the central European Roma population to
determine the prevalence of DFNB49 mutations [29]. Nayak et al. es-
timated the frequency of MARVELD2 mutations 1.5% in a cohort of 800
Pakistani families with ARNSHL [30]. Our study is the second study
which shows the DFNB49 HL in Iran. We obtained the frequency of 5%
(1 family) among the 20 families negative for GJB2 mutations in this
study. This might suggest that MARVELD2 mutations should be con-
sidered in the diagnosis of HL in Iran.
In summary, we identiﬁed a novel variant in the MARVELD2 gene
(DFNB49). The gene should be studied in larger series of families in Iran
for a more thorough understanding of its role in causing HL. While GLA
is a cost eﬀective and reliable method to study genetic diseases, using
GLA in studying heterogeneous disorders like HL with numerous known
loci; may be time consuming and expensive. However, in situations
where there is limited access to NGS technologies, it seems logical to
apply GLA for common loci. This study highly recommends the appli-
cation of the NGS methods in the study of heterogeneous disorders such
as HL.
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